Brivanib-impurities | Pharmaffiliates

brivanib

"Brivanib has been investigated for the treatment of Solid Tumors, Hepato Cellular Carcinoma (HCC), and Metastatic Colorectal Cancer (MCRC). It is under investigation for the treatment of HepatoCellular Carcinoma. . Reference standards of Brivanib API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below

stdClass Object
(
    [pname] => Brivanib - API Standards 
    [catalogue_number] => PA 02 45000
    [category_ids] => ,69,78,70,82,89,
    [chemical_name] => 
    [weight] => 370.38
    [form] => C19H19FN4O3
    [cas] => 649735-46-6
    [pslug] => 649735-46-6-brivanib-api-pa0245000
    [latest_product] => 0
    [linkproducts] => 0
    [offers_id] => 
    [offers_name] => 
    [offers_status] => 
    [offers_start_date] => 
    [offers_end_date] => 
    [pageview] => 
    [offers_slug] => 
    [offers_product_id] => 
    [offers_product_code] => 
    [offers_master_id] => 
    [offer_percentage] => 
    [offers_product_main_cat] => 
)
PA 02 45000

Brivanib - API Standards


  • Catalogue No.:PA 02 45000

  • CAS :

    649735-46-6

  • Molecular Formula : C19H19FN4O3

  • Molecular Weight : 370.38